Pharmacogenetic Treatments for Drug Addiction: Cocaine, Amphetamine and Methamphetamine

REFERENCES

• Giacomini K. M., Brett C. M., Altman R. B., Benowitz N. L., Dolan M. E., Flockhart D. A., Johnson J. A., Hayes D. F., Kelein T., Krauss R. M., Kroetz D. L., McLeod H. L., Nguyen A. T., Ratain M. J., Relling M. V., Reuss V., Roden D. M., Schaefer C. A., Shuldiner A. R., Skaar T., Tantisira K. T.R.F., Wang L., Weinshilboum R. M., Weiss S. T., Zineh I., Network P. R. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007; 81(3)328–45
   PubMed Web of Science ®Google Scholar
• Liao G., Zhang X., Clark D. J., Peltz G. A genomic “roadmap” to “better” drugs. Drug Metab Rev. 2008; 40(2)225–239
   PubMed Web of Science ®Google Scholar
• Drolet B., Simard C., Mizoue L., Roden D. M. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest. 2005; 115(8)
   PubMed Web of Science ®Google Scholar
• Simard C., Drolet B., Yang P. R.B., K., Roden D. M. Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther. 2005; 77(3)138–44
   PubMed Web of Science ®Google Scholar
• Gurbel P. A., Bliden K. P., Hiatt B. L., O'Connor C. M. Clopidogrel for coronary stenting: reponsive variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107(23)
   PubMed Web of Science ®Google Scholar
• Tantisira K. G., Hwang E. S., Raby B. A., Silverman E. S., Lake S. L., Richter B. G., Peng S. L., Drazen J. M., Glimcher L. H., Weiss S. T. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA. 2004; 101(52)18099–104
   PubMed Web of Science ®Google Scholar
• Johnson J. A. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 2003; 19(11)660–6
   PubMed Web of Science ®Google Scholar
• Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Savion N., Varon D., Hod H. Clopidogrel resistance is associated with inicreased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109(25)3171–5
   PubMed Web of Science ®Google Scholar
• Weiss S. T., Litonju A. A., Lange C., Lazarus R., Liggett S. B., Bleecker E. R., Tantisira K. G. Overview of the pharmacogenetics of asthma treatment. Pharmacogenetics J. 2006; 6(5)311–26
   PubMed Web of Science ®Google Scholar
• Paez J. G., Janne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F. J., Lindeman N., Boggon T. J., Naoki K., Sasaki H., Fujii Y., Eck M. J., Sellers W. R., Johnson B. E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676)1497–500
   PubMed Web of Science ®Google Scholar
• Holleman A., Cheok M. H., Den Boer M. L., Yang W., Veerman A. J., Kazemier K. M., Pei D., Cheng C., Pui C. H., Relling M. V., Janka-Schaub G. E., Pieters R., Evans W. E. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and reponse to treatment. N Engl J Med 2004; 351(6)601–3
   PubMed Web of Science ®Google Scholar
• Goetz M. P., Rae J. M., Suman V. J., Safgren S. L., Ames M. M., Visscher D. W., Reynolds C., Couch F. J., Lingle W. L., Flockhart D. A., Desta Z., Perez E. A., Ingle J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of eficacy and hot flashes. J Clin Oncol. 2005; 23(36)9312–8
   PubMed Web of Science ®Google Scholar
• Roses A. D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004; 5(9)645–56
   PubMed Web of Science ®Google Scholar
• Shields A. E., Lerman C. Anticipating clinical intetration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?. Clin Pharmacol Ther. 2008; 83(4)635–639
   PubMed Web of Science ®Google Scholar
• Sofuoglu M., Kosten T. R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Investig Drugs. 2006; 11(1)91–98
   Google Scholar
• O'Brien C. P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005; 162(8)1423–1431
   PubMed Web of Science ®Google Scholar
• Malhotra A. K., Murphy G. M. J., Kennedy J. L. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161(5)780–96
   PubMed Web of Science ®Google Scholar
• Murphy G. M. J., Kremer C., Rodrigues H. E., Schatzberg A. F. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160(10)1830–5
   PubMed Web of Science ®Google Scholar
• Gupta S., Jain S., Brahmachari S. K., Kukreti R. Pharmacogenetics: a path to predictive medicine for schizophrenia. Pharmacogenomics. 2006; 7(1)
   PubMed Web of Science ®Google Scholar
• deLeon J., Armstrong S. C., Cozza K. L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics. 2006; 47(1)75–85
   PubMed Web of Science ®Google Scholar
• Rogers J. F., Nafziger A. N., Bertino J. S. J. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002; 113(9)746–50
   PubMed Web of Science ®Google Scholar
• Scordo M. G., Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 2002; 3(2)201–18
   PubMed Web of Science ®Google Scholar
• Zhang X. Y., Zhou D. F., Wu G. Y., Cao L. Y., Tan Y. L., Haile C. N., Li J., Lu L., Kosten T. A., Kosten T. R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropharmacology 2008; 33(9)2200–2205
   Google Scholar
• Zhang X. Y., Tan Y. L., Zhou D. F., Cao L. Y., Wu G. Y., Haile C. N., Kosten T. A., Kosten T. R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry. 2007; 68(5)754–760
   PubMed Web of Science ®Google Scholar
• Laje G., Paddock S., Manji H., Rush A. J., Wilson A. F., Charney D. S., McMahon F. J. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164: 1530–1538
   PubMed Web of Science ®Google Scholar
• Leshner A. I. Addiction is a brain disease, and it matters. Science 1997; 278(5335)45–47
   PubMed Web of Science ®Google Scholar
• Weisner C., Matzger H., Kaskutas L. A. How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction 2003; 98(7)901–11
   PubMed Web of Science ®Google Scholar
• Simpson D. D., Joe G. W., Broome K. M. A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 2002; 59(6)538–65
   PubMed Web of Science ®Google Scholar
• Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005; 6(7)521–532
   PubMed Web of Science ®Google Scholar
• Yacubian J., Sommer T., Schroeder K., Glascher J., Braus D. F., Buchel C. Subregions of the ventral striatum show preferential coding of reward magnitude and probability. Neuroimage. 2007; 38(3)557–63
   PubMed Web of Science ®Google Scholar
• Haile C. N., Hiroi N., Nestler E. J., Kosten T. A. Differential behavioral responses to cocaine are associated with dynamics of mesolimbic dopamine proteins in Lewis and Fischer 344 rats. Synapse 2001; 41: 179–190
   PubMed Web of Science ®Google Scholar
• Haile C. N., Kosten T. R., Kosten T. A. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet. 2007; 37(1)119–45
   PubMed Web of Science ®Google Scholar
• Haile C. N., Kosten T. A. Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. J Pharmacol Exp Ther. 2001; 299(2)509–18
   PubMed Web of Science ®Google Scholar
• Gabbay F. H. Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol. 2003; 11(1)91–101
   PubMed Web of Science ®Google Scholar
• Lott D. C., Kim S. J., Cook E. H. J., de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005; 30(3)602–609
   PubMed Web of Science ®Google Scholar
• Haile C. N., Kosten T. A., Kosten T. R. Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates. Am J Drug Alcohol Abuse 2008; 34: 355–381
   PubMed Web of Science ®Google Scholar
• Nestler E. J. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005; 8(11)1445–1449
   PubMed Web of Science ®Google Scholar
• Heffner T. G., Hartman J. A., Seiden L. S. Feeding increases dopamine metabolism in the rat brain. Science 1980; 208: 1168–1170
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wise R. A. How can drug addiction help us understand obesity?. Nat Neurosci. 2005; 8(5)555–60
   PubMed Web of Science ®Google Scholar
• Robinson T. E., Berridge K. C. Addiction. Annu Rev Psychol. 2003; 54: 75–114
   Web of Science ®Google Scholar
• Hyman S. E., Malenka R. C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2001; 2(10)695–703
   PubMed Web of Science ®Google Scholar
• Everitt B. J., Cardinal R. N., Parkinson J. A., Robbins T. W. Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning. Ann NY Acad Sci. 2003; 985: 233–50
   PubMed Web of Science ®Google Scholar
• Kalivas P. W. Glutamate systems in cocaine addiction. Curr Opin Pharmacol. 2004; 4(1)23–9
   PubMed Web of Science ®Google Scholar
• Roberts D. C., Koob G. F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental. Pharmacol Biochem Behav. 1982; 17: 901–904
   PubMed Web of Science ®Google Scholar
• DiChiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988; 85: 5274–5278
   PubMed Web of Science ®Google Scholar
• Pettit H. O., Ettenberg A., Bloom F. E., Koob G. F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology 1984; 84: 167–173
   PubMed Web of Science ®Google Scholar
• Zito K. A., Vickers G., Roberts D. C. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol Biochem Behav. 1985; 23: 1029–1036
   PubMed Web of Science ®Google Scholar
• Glowinski J., Iversen L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966; 13: 655–669
   PubMed Web of Science ®Google Scholar
• Snyder S. H., Coyle J. T. Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther. 1969; 165: 78–86
   PubMed Web of Science ®Google Scholar
• Lewis D. A., Melchitzky D. S., Sesack S. R., Whitehead R. E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 2001; 432(1)119–36
   PubMed Web of Science ®Google Scholar
• Mazei M. S., Pluto C. P., Kirkbride B., Pehek E. A. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res. 2002; 936(1–2)58–67
   PubMed Web of Science ®Google Scholar
• Moron J. A., Brockington A., Wise R. A., Rocha B. A., Hope B. T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002; 22(2)389–95
   PubMed Web of Science ®Google Scholar
• Nestler E. J. Molecular neurobiology of addiction. Am J Addict. 2001; 10: 201–217
   PubMed Web of Science ®Google Scholar
• Greengard P., Allen P. B., Nairn A. C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435–447
   PubMed Web of Science ®Google Scholar
• Terwilliger R. Z., Beitner-Johnson D., Sevarino K. A., Crain S. M., Nestler E. J. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 1991; 548: 100–110
   PubMed Web of Science ®Google Scholar
• Pierce R. C., Kalivas P. W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 1997; 25: 192–216
   PubMed Web of Science ®Google Scholar
• Schank J. R., Liles L. C., Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry 2008; 63(11)1007–1012
   PubMed Web of Science ®Google Scholar
• Robinson T. E., Berridge K. C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993; 18: 247–291
   PubMed Web of Science ®Google Scholar
• Bartlett E., Hallin A., Chapman B., Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability?. Neuropsychopharmacology. 1997; 16(1)77–82
   PubMed Web of Science ®Google Scholar
• Gawin F. H., Kleber H. D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986; 43(2)107–13
   PubMed Web of Science ®Google Scholar
• Hart C. L., Ward A. S., Haney M., Foltin R. W., Fischman M. W. Methamphetamine self-administration by humans. Psychopharmacology 2001; 157: 75–81
   PubMed Web of Science ®Google Scholar
• Fischman M. W., Schuster C. R. Cocaine self-administration in humans. Fed Proc. 1982; 41: 241–246
   PubMedGoogle Scholar
• Wachtel S. R., de Wit H. Subjective and behavioral effects of repeated d-amphetamine in humans. Behav Pharm. 1999; 10(3)271–81
   PubMed Web of Science ®Google Scholar
• Vollm B. A., deAraujo I. E., Cowen P. J., Rolls E. T., Kringelbach M. L., Smith K. A., Jessard P., Heal R. J., Matthews P. M. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology. 2004; 29: 1715–1722
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Gifford A., Hitzemann R., Ding Y. S., Pappas N. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999; 156(9)1440–3
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R., Chen A. D., Dewey S. L., Pappas N. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386(6627)830–3
   PubMed Web of Science ®Google Scholar
• Laruelle M., Gelernter J., Innis R. B. D2 receptors binding potential is not affected by Taq1 polymorphisms at the D2 receptor gene. Mol Psychiatry. 1998; 3(3)261–5
   PubMed Web of Science ®Google Scholar
• Romach M. K., Glue P., Kampman K., Kaplan H. L., Somer G. R., Poole S., Clarke L., Coffin V., Cornish J., O'Brien C. P., Sellers E. M. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry. 1999; 56(12)1101–6
   PubMed Web of Science ®Google Scholar
• Sherer M. A., Kumor K. M., Jaffe J. H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 1989; 27(2)117–25
   PubMed Web of Science ®Google Scholar
• Newton T. F., Ling W., Kalechstein A. D., Uslaner J., Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 2001; 102(3)227–33
   PubMed Web of Science ®Google Scholar
• Alhassoon O. M., Dupont R. M., Schweinsburg B. C., Taylor M. J., Patterson T. L., Grant I. Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism. Int J Neuropsychopharmacol. 2001; 4: 105–112
   PubMed Web of Science ®Google Scholar
• Hall F. S., Sora I., Drgonova J., Li X. F., Goeb M., Uhl G. R. Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci. 2004; 1025: 47–56
   PubMed Web of Science ®Google Scholar
• Shoptaw S., Watson D. W., Reiber C., Rawson R. A., Montgomery M. A., Majewska M. D., Ling W. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005; 11(1)78–90
   Web of Science ®Google Scholar
• Kosten T. R., George T. P., Kosten T. A. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002; 11(4)491–499
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Morgan C., Kosten T. A. Treatment of heroin addicts using buprenorphine.H. Am J Drug Alcohol Abuse 1991; 17(2)119–28
   PubMed Web of Science ®Google Scholar
• Shoptaw S., Yang X., Rotheram-Fuller E. J., Hsieh Y. C., Kintaudi P. C., Charuvastra V. C., Ling W. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003; 64(12)1440–1448
   PubMed Web of Science ®Google Scholar
• Gonzalez G., Servarino K., Sofuoglu M., Poling J., Oliveto A., Gonsai K., George T. P., Kosten T. R. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003; 98(11)1625–32
   PubMed Web of Science ®Google Scholar
• Hameedi F. A., Rosen M. I., McCance -Katz E. F., McMahon T. J., Price L. H., Jatlow P. I., Woods S. W., Kosten T. R. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry. 1995; 37(8)560–3
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Fenton L. R., Ball S. A., Nich C., Frankforter T. L., Shi J., Rounsaville B. J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264–272
   PubMed Web of Science ®Google Scholar
• Cubells J. F., Zabetian C. P. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology 2004; 174(4)463–76
   PubMed Web of Science ®Google Scholar
• Mikami L. R., Wieseler S., Souza R. L., Schopfter L. M., Nachon F., Lockridge O., Chautard-Freire-Maia E. A. Five new naturally occurring mutations of the BCHE gene and frequencies of 12 butyrylcholinesterase alleles in a Brazilian population. Pharmacogenet Genomics. 2008; 18(3)213–218
   PubMed Web of Science ®Google Scholar
• Towell J. F. r., Cho J. K., Roh B. L., Wang R. I. Disulfiram and erythrocyte aldehyde dehydrogenase inhibition. Clin Pharmacol Ther. 1983; 33(4)517–21
   PubMed Web of Science ®Google Scholar
• Johnson S. M., Fleming W. W. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev. 1989; 41(4)435–88
   PubMed Web of Science ®Google Scholar
• Vaccari A., Saba P. L., Ruiu S., Collu M., Devoto P. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol. 1996; 139(1)102–8
   PubMed Web of Science ®Google Scholar
• Bourdelat-Parks B. N., Anderson G. M., Donaldson Z. R., Weiss J. M., Bonsall R. W., Emery M. S., Liles L. C., Weinshenker D. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology 2005; 183(1)72–80
   PubMed Web of Science ®Google Scholar
• Schank J. R., Ventura R., Puglisi-Allegra S., Alcaro A., Cole C. D., Liles L. C., Seeman P., Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology. 2006; 31(10)2221–30
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Kosten T. R., Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry 1998; 43(7)540–3
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Kosten T. R., Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998; 52(1)27–39
   PubMed Web of Science ®Google Scholar
• Wright C., Moore R. D. Disulfiram treatment of alcoholism. Am J Med. 1990; 88(6)647–55
   PubMed Web of Science ®Google Scholar
• Suh J. J., Pettinati H. M., Kampman K. M., O'Brien C. P. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006; 26(3)290–302
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Nich C., Ball S. A., McCance E., Rounsavile B. J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93(5)713–27
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Power M. E., Bryant K., Rounsaville B. J. One-year follow-up status of treatment-seeking cocaine abusers. Psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993; 181(2)71–9
   PubMed Web of Science ®Google Scholar
• George T. P., Chawarski M. C., Pakes J., Carroll K. M., Kosten T. R., Schottenfeld R. S. Disulfiram versus placebo for cocaine dependence in buprenorphine maintained subjects: a preliminary trial. Biol Psychiatry 2000; 47(12)1080–6
   PubMed Web of Science ®Google Scholar
• Higgins S. T., Budney A. J., Bickel W. K., Hughes J. R., Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993; 150(4)675–6
   PubMed Web of Science ®Google Scholar
• Petrakis I. L., Carroll K. M., Nich C., Gordon L. T., McCance-Kat z E. F., Frankforter T. L., Rounsaville B. J. Disulfiram treatment for cocaine dependence in methadone maintained opioid addicts. Addiction 2000; 95(2)219–28
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Price L. H., McDougle C. J., Kosten T. R., Black J. E., Jatlow P. I. Concurrent cocaine ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology 1993; 111(1)39–46
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Nich C., Ball S. A., McCance E., Frankforter T. L., Rounsaville B. J. One year followup of disulfiram and psychotherapy for cocaine alcohol users: sustained effects of treatment. Addiction 2000; 95(9)1335–49
   PubMed Web of Science ®Google Scholar
• Martensen-Larsen O. Psychotic phenomena provoked by tetraethylthiuram disulfide. Q J Stud Alcohol. 1951; 12(2)206–16
   PubMedGoogle Scholar
• Kalayasiri R., Sughondhabirom A., Gueorguieva R., Coric V. L., W.J., Morgan P. T., Cubells J. F., Malison R. T. Selfreported paranoia during laboratory “binge” cocaine selfadministration in humans. Pharmacol Biochem Behav. 2006; 83(2)249–56
   PubMed Web of Science ®Google Scholar
• Baker J. R., Jatlow P., McCance -Katz E. F. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007; 87(2–3)202–9
   PubMed Web of Science ®Google Scholar
• Haile C. N., During M. J., Jatlow P. I., Kosten T. R., Kosten T. A. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol Psychiatry 2003; 54: 915–921
   PubMed Web of Science ®Google Scholar
• Cubells J. F., Kranzler H. R., McCance-Katz E. F., Anderson G. M., Malison R. T., Price L. H., Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry. 2000; 5(1)56–63
   PubMed Web of Science ®Google Scholar
• Stewart L. C., Klinman J. P. Dopamine beta-hydroxylase of adrenal chromaffin granules: structure and function. Annu Rev Biochem. 1988; 57: 551–592
   PubMed Web of Science ®Google Scholar
• Kaufman S., Friedman S. Dopamine-beta-hydroxylase. Pharmacol Rev. 1965; 17: 71–100
   PubMed Web of Science ®Google Scholar
• Senard J.-M., Rouet P. Dopamine beta-hydroxylase deficiency. Orphanet J Rare Dis 2006; 1(7)1–4
   Google Scholar
• Deinum J., Steenbergen-Spanjers G. C., Jansen M., Boomsma F., Lenders J. W., van Ittersum F. J., Hück N., van den Heuvel L. P., Wevers R. A. DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome. A. J Med Genet. 2004; 41(4)e38
   Web of Science ®Google Scholar
• Garland E. M., Black B. K., Harris P. A., Harris D. R. Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2007; 293: H684–H690
   PubMed Web of Science ®Google Scholar
• Grzanna R., Coyle J. T. Immunochemical studies on the turnover of rat serum dopamine beta-hydroxylase. Mol Pharmacol. 1977; 13(5)956–964
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. M. Serum dopamine beta-hydroxylase. Pharmacol Rev. 1978; 30(2)133–66
   PubMed Web of Science ®Google Scholar
• Paclt I., Koudelová J. Changes of dopamine-beta-hydroxylase activity during ontogenesis in healthy subjects and in an experimental model (rats). Physiol Res. 2004; 53(6)661–7
   PubMed Web of Science ®Google Scholar
• Ross S. B., Wetterberg L., Myrhed M. Genetic control of plasma dopamine-beta-hydroxylase. Life Sci. 1973; 12(12)529–32
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. M., Raymond F. A., Elveback L. R., Weidman W. H. Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science 1973; 181(103)943–945
   PubMed Web of Science ®Google Scholar
• Oxenstierna G., Edman G., Iselius L., Oreland L., Ross S. B., Sedvall G. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals–a genetic study. J Psychiatr Res. 1986; 20(1)19–29
   PubMed Web of Science ®Google Scholar
• Wei J., Ramchand C. N., Hemmings G. P. Possible control of dopamine beta-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum Genet. 1997; 99(1)52–5
   PubMed Web of Science ®Google Scholar
• Cubells J. F., vanKammen D. P., Kelley M. E., Anderson G. M., O'Connor D. T., Price L. H., Malison R. T., Rao P. A., Kobayashi K., Nagatsu T., Gelernter J. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet. 1998; 102(5)533–540
   PubMed Web of Science ®Google Scholar
• Zabetian C. P., Anderson G. M., Buxbaum S. G., Elston R. C., Ichinose H., Nagatsu T., Kim K. S., Kim C. H., Malison R. T., Gelernter J., Cubells J. F. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Genet. 2001; 68(2)515–522
   Web of Science ®Google Scholar
• Zabetian C. P., Buxbaum S. G., Elston R. C., Kohnke M. D., Anderson G. M., Gelernter J., Cubells J. F. The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Genet. 2003; 72(6)1389–1400
   Web of Science ®Google Scholar
• Kohnke M. D., Zabetian C. P., Anderson G. M., Kolb W., Gaertner I., Buchkremer G., Vonthein R., Schick S., Lutz U., Kohnke A. M., Cubells J. F. A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry 2002; 52(12)1151–1158
   PubMed Web of Science ®Google Scholar
• Bhaduri N., Mukhopadhyay K. Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: A study on eastern Indian populaion. Cell Mol Neurobiol 2008; 28: 343–350
   PubMed Web of Science ®Google Scholar
• Cadet J.-L., Jayanthi S., Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 2003; 17: 1775–1788
   PubMed Web of Science ®Google Scholar
• Tang Y. L., Epstein M. P., Anderson G. M., Zabetian C. P., Cubells J. F. Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet. 2007; 15(8)878–83
   PubMed Web of Science ®Google Scholar
• Guindalini C., Laranjeira R., Collier D., Messas G., Vallada H., Breen C. Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Funct 2008; 3(4)1–4
   Web of Science ®Google Scholar
• Tsuang M. T., Lyons M. J., Meyer J. M., Doyle T., Eisen S. A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998; 55(11)967–72
   PubMed Web of Science ®Google Scholar
• Wei J., Ramchand C. N., Hemmings G. P. TaqI polymorphic sites at the human dopamine beta-hydroxylase gene possibly associated with biochemical alterations of the catecholamine pathway in schizophrenia. Psychiatr Genet. 1998; 8(1)19–24
   PubMed Web of Science ®Google Scholar
• Cubells J. F., Price L. H., Meyers B. S., Anderson G. M., Zabetian C. P., Alexopoulos G. S., Nelson J. C., Sanacora G., Kirwin P., Carpenter L., Malison R. T., Gelernter J. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry 2002; 51(5)358–64
   PubMed Web of Science ®Google Scholar
• Freire M. T., Hutz M. H., Bau C. H., The D BH. 1021 C/T polymorphism is not associated with alcoholism but possibly with patients' exposure to life events. J Neural Transm. 2005; 112(9)1269–74
   PubMed Web of Science ®Google Scholar
• Tang Y., Buxbaum S. G., Waldman I., Anderson G. M., Zabetian C. P., Köhnke M. D., Cubells J. F. A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biol Psychiatry 2006; 60(10)1034–8
   PubMed Web of Science ®Google Scholar
• Mustapic M., Pivac N., Kozaric-Kovacic D., Dezeljin M., Cubells J. F., Muck-Seler D. Dopamine beta-hydroxylase (DBH) activity and -1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet. 2007; 144(8)1087–9
   Web of Science ®Google Scholar
• Rogeness G. A., Maas J. W., Javors M. A., Macedo C. A., Harris W. R., Hoppe S. K. Diagnoses, catecholamine metabolism, and plasma dopamine-beta-hydroxylase. J Am Acad Child Adolesc Psychiatry. 1988; 27(1)121–5
   PubMed Web of Science ®Google Scholar
• Rogeness G. A., Javors M. A., Maas J. W., Macedo C. A., Fischer C. Plasma dopamine-beta-hydroxylase, HVA, MHPG, and conduct disorder in emotionally disturbed boys. Biol Psychiatry. 1987; 22(9)1158–62
   PubMed Web of Science ®Google Scholar
• Rogeness G. A., Hernandez J. M., Macedo C. A., Mitchell E. L., Amrung S. A., Harris W. R. Clinical characteristics of emotionally disturbed boys with very low activities of dopamine-beta-hydroxylase. J Am Acad Child Psychiatry. 1984; 23(2)203–8
   PubMedGoogle Scholar
• Rogeness G. A., Hernandez J. M., Macedo C. A., Amrung S. A., Hoppe S. K. Near-zero plasma dopamine-beta-hydroxylase and conduct disorder in emotionally disturbed boys. J Am Acad Child Psychiatry. 1986; 25(4)521–7
   PubMedGoogle Scholar
• Galvin M., Shekhar A., Simon J., Stilwell B., Ten Eyck R., Laite G., Karwisch G., Blix S. Low dopamine-beta-hydroxylase: a biological sequela of abuse and neglect?. Psychiatry Res. 1991; 39(1)1–11
   PubMed Web of Science ®Google Scholar
• Healy D. G., Abou-Sleiman P. M., Ozawa T., Lees A. J., Bhatia K., Ahmadi K. R., Wullner U., Berciano J., Moller J. C., Kamm C., Burk K., Barone P., Tolosa E., Quinn N., Goldstein D. B., Wood N. W. A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol. 2004; 55(3)443–6
   PubMed Web of Science ®Google Scholar
• Jonsson E. G., Bah J., Melke J., Abou Jamra R., Schumacher J., Westberg L., Ivo R., Cichon S., Propping P., Nathen M. M., Eriksson E., Sedvall G. C. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry. 2004; 4(4)
   PubMed Web of Science ®Google Scholar
• Kalayasiri R., Sughondhabirom A., Gueorguieva R., Coric V., Lynch W. J., Lappalainen J., Gelernter J., Cubells J. F., Malison R. T. Dopamine beta-hydroxylase gene (DbetaH) -1021C–T influences self-reported paranoia during cocaine self-administration. Biol Psychiatry. 2007; 61(11)1310–3
   PubMed Web of Science ®Google Scholar
• Sughondhabirom A., Jain D., Gueorguieva R., Corvic V., Berman R., Lynch W. J., Self D. W., Jatlow P. R.T., M. A paradigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology 2005; 180(3)436–46
   PubMed Web of Science ®Google Scholar
• Brady K. T., Lydiard R. B., Malcolm R., Ballenger J. C. Cocaine-induced psychosis. J Clin Psychiatry. 1991; 52(12)509–12
   PubMed Web of Science ®Google Scholar
• Satel S. L., Edell W. S. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991; 148(12)1708–11
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wang G. J., Fowler J. S., Logan J., Hitzemann R., Ding Y. S., Pappas N., Shea C., Piscani K. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 1996; 20: 1594–1598
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Fowler J. S., Wolf A. P., Schlyer D., Shiue C. Y., Alpert R., Dewey S. L., Logan J., Bendriem B., Christman D., et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990; 147(6)719–24
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Chang L., Wang G. J., Fowler J. S., Franceschi D., Sedler M. J., Gately S. J., Hitzemann R., Ding Y. S., Wong C., Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry. 2001; 158: 383–389
   PubMed Web of Science ®Google Scholar
• Wang G. J., Volkow N. D., Fowler J. S., Logan J., Abumrad N. N., Hitzemann R. J., Pappas N. S., Pascani K. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropharmacology 1997; 16(2)174–82
   Google Scholar
• Volkow N. D., Wang G. J., Fowler J. S., Thanos P., Logan J., Gatley S. J., Gifford A., Ding Y. S., Wong C., Pappas N., Brain D A. D2 receptors predict reinforcing effects of stimulants in humans: replications study. Synapse 2002; 46(2)79–82
   PubMed Web of Science ®Google Scholar
• Zubieta J. K., Gorelick D. A., Stauffer R., Ravert H. T., Dannals R. F., Frost J. J. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996; 2(11)1225–9
   PubMed Web of Science ®Google Scholar
• Heinz A., Siessmeier T., Wrase J., Hermann D., Klein S., Grüsser S. M., Flor H., Braus D. F., Buchholz H. G., Gründer G., Schreckenberger M., Smolka M. N., Rösch F., Mann K., Bartenstein P. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004; 161(10)1741–2
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wang G. J., Begleiter H., Porjesz B., Fowler J. S., Telang F., Wong C., Ma Y., Logan J., Goldstein R. Z., Alexoff D., Thanos P. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry. 2006; 63(9)999–1008
   PubMed Web of Science ®Google Scholar
• Dalley J. W., Fryer T. D., Brichard L., Robinson E. S., Theobald D. E., Lääne K., Peña Y., Murphy E. R., Shah Y., Probst K., Abakumova I., Aigbirhio F. I., Richards H. K., Hong Y., Baron J. C., Everitt B. J., Robbins T. W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007; 315(5816)1267–70
   PubMed Web of Science ®Google Scholar
• Flores G., Wood G. K., Barbeau D., Queirion R., Srivastava L. K. Lewis and Fischer rats: a comparison of dopamine transporter and receptor levels. Brain Res. 1998; 814(1–2)34–40
   PubMed Web of Science ®Google Scholar
• Stefanini E., Frau M., Garau M. G., Garau B., Fadda F., Gessa G. L. Alcohol-preferring rats have fewer dopamine D2 receptors in the limbic system. Alcohol Alcohol. 1992; 27(2)127–30
   PubMed Web of Science ®Google Scholar
• McBride W. J., Chernet E., Dyr W., Lumeng L., Li T. K. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol. 1993; 10(5)387–90
   PubMed Web of Science ®Google Scholar
• Maldonado R., Saiardi A., Valverde O., Samad T. A., Roques B. P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 1997; 388(6642)586–9
   PubMed Web of Science ®Google Scholar
• Phillips T. J., Brown K. J., Burkhart-Kasch S., Wenger C. D., Kelly M. A., Rubinstein M., Grandy D. K., Low M. J. Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. Nat Neurosci. 1998; 1(2)610–5
   PubMed Web of Science ®Google Scholar
• Wang G. J., Volkow N. D., Chang L., Miller E., Sedler M., Hitzemann R., Zhu W., Logan J., Ma Y., Fowler J. S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004; 31: 313–319
   Google Scholar
• Kawarai T., Kawakami H., Yamamura Y., Nakamura S. Structure and organization of the gene encoding human dopamine transporter. Gene 1997; 195(1)11–8
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Wang G. J., Fowler J. S., Gatley S. J., Ding Y. S., Logan J., Dewey S. L., Hitzemann R., Lieberman J. Relationship between psychostimulant-induced “high” and dopamine transporter occupancy. Proc Natl Acad Sci U S A. 1996; 93(19)10388–92
   PubMed Web of Science ®Google Scholar
• Ritz M. C., Lamb R. J., Goldberg S. R., Kuhar M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987; 237: 1219–1223
   PubMed Web of Science ®Google Scholar
• Sulzer D., Sonders M. S., Poulsen N. W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog in Neurobiol. 2005; 75: 406–433
   PubMed Web of Science ®Google Scholar
• Liang N. Y., Rutledge C. O. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol. 1982; 31: 983–992
   PubMed Web of Science ®Google Scholar
• Haile C. N. Neurochemical and Neurobehavioral consequences of methamphetamine abuse. Drug Abuse Handbook, Second Ed., S. B. Karch. CRC Press, Boca Raton, FL, 33487 2007; 478–503
   Google Scholar
• Giros B., Jaber M., Jones S. R., Wightman R. M., Caron M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379(6566)606–612
   PubMed Web of Science ®Google Scholar
• Mitchell R. J., Howlett S., Earl L., White N. G., McComb J., Schanfield M. S., Briceno I., Papiha S. S., Osipova L., Livshits G., Leonard W. R., Crawford M. H. Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations. Hum Biol. 2000; 72(2)295–304
   PubMed Web of Science ®Google Scholar
• Doucette-Stamm L A. B. D., Tian J, Mockus S, Mao J I. Population genetic study of the human dopamine transporter gene (DAT1). Genet Epidemiol. 1995; 12(3)303–8
   PubMed Web of Science ®Google Scholar
• Kang A. M., Palmatier M. A., Kidd K. K. Global variation of a 40-bp VNTR in the 3′ -untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 1999; 46(2)151–60
   PubMed Web of Science ®Google Scholar
• Fuke S., Suo S., Takahashi N., Koike H., Sasagawa N., Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001; 1(2)152–156
   PubMedGoogle Scholar
• Mill J., Asherson P., Browes C., D'Souza U., Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 2002; 114(8)975–979
   PubMed Web of Science ®Google Scholar
• VanNess S. H., Owens M. J., Kilts C. D. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005; 27(6)55
   Web of Science ®Google Scholar
• Biederman J., Petty C. R., Wilens T. E., Fraire M. G., Purcell C. A., Mick E., Monuteaux M. C., Faraone S. V. Familial risk analyses of attention deficit hyperactivity disorder adn substance use disorders. Am J Psychiatry 2008; 165(1)107–15
   PubMed Web of Science ®Google Scholar
• Barkley R. A. Psychosocial treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 2002; 63(12)36–43
   PubMed Web of Science ®Google Scholar
• Aylward E. H., Reiss A. L., Reader M. J., Singer H. S., Brown J. E., Denckla M. B. Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J Child Neurol. 1996; 11(2)112–5
   PubMed Web of Science ®Google Scholar
• Castellanos F. X., Giedd J. N., Marsh W. L., Hamburger S. D., Vaituzis A. C., Dickstein D. P., Sarfatti S. E., Vauss Y. C., Snell J. W., Lange N., Kaysen D., Krain A. L., Ritchie G. F., Rajapakse J. C., Rapoport J. L. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1996; 53(7)607–16
   PubMed Web of Science ®Google Scholar
• Ernst M., Zametkin A. J., Matochik J. A., Jons P. H., Cohen R. M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci. 1998; 18(15)5901–7
   PubMed Web of Science ®Google Scholar
• Krause K. H., Dresel S. H., Krause J., Kung H. F., , Tatsch K, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission tomography. Neurosci Lett. 2000; 285(2)107–10
   PubMed Web of Science ®Google Scholar
• Krause K. H., Dresel S. H., Krause J., Kung H. F., , Tatsc K., Lochmuller H, et al. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome adn attention deficit/hyperactivity disorder: positive effect of methylphenidate. J Neurol. 2002; 249(8)1116–8
   PubMed Web of Science ®Google Scholar
• Zametkin A. J., Liebenauer L. L., Fitzgerald G. A., King A. C., Minkunas D. V., Herscovitch P., Yamada E. M., Cohen R. M. Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1993; 50(5)333–40
   PubMed Web of Science ®Google Scholar
• Wilens T. E., Upadhyaya H. P. Impact of substance use disorder on ADHD and its treatment. J Clin Psychiatry. 2007; 68(8)e20
   PubMedGoogle Scholar
• Volkow N. D., Fowler J. S., Wang G. J., Swanson J. M., Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007; 64(11)1575–9
   PubMedGoogle Scholar
• Cook E. H. J., Stein M. A., Krasowski M. D., Cox N. J., Olkon D. M., Kieffer J. E., Leventhal B. L. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 1995; 56(4)993–998
   PubMed Web of Science ®Google Scholar
• Waldman I. D., Rowe D. C., Abramowitz A., Kozel S. T., Mohr J. H., Sherman S. L., Cleveland H. H., Sanders M. L., Gard J. M., Stever C. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnositc subtype and severity. Am J Hum Genet. 1998; 63(6)1767–76
   PubMed Web of Science ®Google Scholar
• Daly G., Hawi Z., Fitzgerald M., Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry. 1999; 4(2)192–6
   PubMed Web of Science ®Google Scholar
• Brookes K. J., Mill J., Guindalini C., Curran S., Xu X., Knight J., Chen C. K., Huang Y. S., Sethna V., Taylor E., Chen W., Breen G., Asherson P. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry. 2006; 63(1)74–81
   PubMed Web of Science ®Google Scholar
• Muglia P., Jain U., Inkster B., Kennedy J. L. A quantitative trait locus analysis of the dopamine transporter gene in adults with ADHD. Neuropsychopharmacology. 2002; 27(4)655–62
   PubMed Web of Science ®Google Scholar
• Kim D. J., Roh S., Kim Y. J., Yoon S. J., Lee H. K., Han C. S., Kim Y. K. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett. 2005; 388(2)112–5
   PubMed Web of Science ®Google Scholar
• Bellgrove M. A., Chambers C. D., Johnson K. A., Daibhis A., Daly M., Hawi Z., Lambert D., Gill M., Robertson I. H. Dopaminergic genotype biases spatial attention in healthy children. Mol Psychiatry. 2007; 12(8)786–92
   PubMed Web of Science ®Google Scholar
• Guindalini C., Howard M., Haddley K., Laranjeira R., Collier D., Ammar N., Craig I., O'Gara C., Bubb V. J., Greenwood T., Kelsoe J., Asherson P., Murray R. M., Castelo A., Quinn J. P., Vallada H., Breen G. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A. 2006; 103(12)4552–7
   PubMed Web of Science ®Google Scholar
• Winsberg B. G., Comings D. E. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry. 1999; 38(12)1474–7
   PubMed Web of Science ®Google Scholar
• Roman T., Rohde L. A., Hutz M. H. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics. 2004; 4(2)83–92
   PubMedGoogle Scholar
• Cheon K. A., Ryu Y. H., Kim J. W., Cho D. Y. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 2005; 15(1)95–101
   PubMed Web of Science ®Google Scholar
• Kooij J. S., Boonstra A. M., Vermeulen S. H., Heister A. G., Burger H., Buitelaar J. K., Franke B. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet. 2007, oct 22 epub
   Google Scholar
• Gilbert D. L., Wang Z., Sallee F. R., Ridel K. R., Merhar S., Zhang J., Lipps T. D., White C., Badreldin N., Wassermann E. M. Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain 2006; 129(8)2038–46
   PubMed Web of Science ®Google Scholar
• Joober R., Grizenko N., Sengupta S., Amor L. B., Schmitz N., Schwartz G., Karama S., Lageix P., Fathalli F. Torkaman-Zehi, A., and Ter Stepanian, M., Dopamine transporter 3′ -UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology. 2007; 32(6)1370–6
   PubMed Web of Science ®Google Scholar
• Mick E., Biederman J., Spencer T., Faraone S. V., Sklar P. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2006; 141(8)890–4
   Web of Science ®Google Scholar
• Krause J., Dresel S. H., Krause K. H., La Fougère C., Zill P., Ackenheil M. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World J Biol Psychiatry. 2006; 7(3)152–7
   PubMed Web of Science ®Google Scholar
• Kirley A., Lowe N., Hawi Z., Mullins C., Daly G., Waldman I., McCarron M., O'Donnell D., Fitzgerald M., Gill M. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2003; 121(1)50–4
   Web of Science ®Google Scholar
• Stein M. A., Waldman I. D., Sarampote C. S., Seymour K. E., Robb A. S., Conlon C., Kim S. J., Cook E. H. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005; 30(7)1374–82
   PubMed Web of Science ®Google Scholar
• Levin F. R., Evans S. M., Brooks D. J., Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007; 87(1)20–9
   PubMed Web of Science ®Google Scholar
• Collins S. L., Levin F. R., Foltin R. W., Kleber H. D., Evans S. M. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 2006; 82(2)158–67
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Hitzemann R., Wang G. J., Fowler J. S., Wolf A. P., Dewey S. L., Handlesman L. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11(3)184–90
   PubMed Web of Science ®Google Scholar
• Rosenkranz J. A., Grace A. A. Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats. J Neurosci. 2001; 21(11)4090–103
   PubMed Web of Science ®Google Scholar
• Goldstein R. Z., Volkow N. D., Chang L., Wang G. J., Fowler J. S., Depue R. A., Gur R. C. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 59(10)1642–52
   Web of Science ®Google Scholar
• Heinz A., Goldman D., Jones D. W., Palmour R., Hommer D., Gorey J. G., Lee K. S., Linnoila M., Weinberger D. R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22(2)133–139
   PubMed Web of Science ®Google Scholar
• Martinez D., Gelernter J., Abi-Dargham A., van Dyck C. H., Kegeles L., Innis R. B., Laruelle M. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001; 24(5)553–560
   PubMed Web of Science ®Google Scholar
• Jacobsen L. K., Staley J. K., Zoghbi S. S., Seibyl J. P., Kosten T. R., Innis R. B., Gelernter J. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 2000; 157(10)1700–1703
   PubMed Web of Science ®Google Scholar
• van Dyck C. H., Malison R. T., Jacobsen L. K., Seibyl J. P., Staley J. K., Laruelle M., Baldwin R. M., Innis R. B., Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 2005; 46(5)745–751
   PubMed Web of Science ®Google Scholar
• Jonsson E. G., Nothen M. M., Gustavsson J. P., Neidt H., Bunzel R., Propping P., Sedvall G. C. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res. 1998; 79(1)1–9
   PubMed Web of Science ®Google Scholar
• Laruelle M., Abi-Dargham A., VanDyck C. H., Rosenblatt W., Zea-Ponce Y., Zonghbi S. S., Baldwin R. M., Charney D. S., Hoffer P. B., Kung H. F., et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995; 36(7)1182–90
   PubMed Web of Science ®Google Scholar
• Miller M. A., Hughes A. L. Epidemiology of amphetamine use in teh United States. Amphetamine and its Analogs, A. K. Cho, D. S. Segal. Academic Press, San Diego 1994; 503
   Google Scholar
• Robbins T. W. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res. 2000; 133(1)130–8
   PubMed Web of Science ®Google Scholar
• Kimberg D. Y., D'Esposito M., Farah M. J. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport. 1997; 8(16)1–5
   Web of Science ®Google Scholar
• Mehta M. A., Owen A. M., Sahakian B. J., Mavaddat N., Pickard J. D., Robbins T. W. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000; 20(6)RC65
   PubMed Web of Science ®Google Scholar
• Mitchell S. H., Laurent C. L., de Wit H. Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. Psychopharmacology 1996; 125(4)371–8
   PubMed Web of Science ®Google Scholar
• Cesarec Z., Nyman A. K. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand. 1985; 71(5)523–38
   PubMed Web of Science ®Google Scholar
• Hutchison K. E., Wood M. D., Swift R. Personality factors moderate subjective and psychophysiological responses to d-amphetamine in humans. Exp Clin Psychopharmacol. 1999; 7(4)493–501
   PubMed Web of Science ®Google Scholar
• White T. L., Justice A. J., de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002; 73(4)729–41
   PubMed Web of Science ®Google Scholar
• Mattay V. S., Goldberg T. E., Fera F., Hariri A. R., Tessitore A., Egan M. F., Kolachana B., Callicott J. H., Weinberger D. R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003; 100(10)6186–91
   PubMed Web of Science ®Google Scholar
• Dlugos A., Freitag C., Hohoff C., McDonald J. S., Cook E. H., Deckert J., de Wit H. Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007; 61(11)1296–305
   PubMed Web of Science ®Google Scholar
• Lott D. C., Kim S. J., Cook E. H., de Wit H. Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict. 2006; 15(5)327–35
   PubMed Web of Science ®Google Scholar
• Hohoff C., McDonald J. M., Baune B. T., Cook E. H., Deckert J., de Wit H. Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet. 2005; 139(1)42–4
   Web of Science ®Google Scholar
• Veenstra-VanderWeele J., Qaadir A., Palmer A. A., Cook E. H. J., de Wit H. Association between the casein kinase 1 epsilon gene region and subjective response to Damphetamine. Neuropsychopharmacology. 2006; 31(5)1056–63
   PubMed Web of Science ®Google Scholar
• Flanagin B. A., Cook E. H. J., de Wit H. An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet. 2006; 141(6)576–83
   Web of Science ®Google Scholar
• Vandenbergh D. J., Persico A. M., Hawkins A. L., Griffin C. A., Li X., Jabs E. W., Uhl G. R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992; 14(4)1104–1106
   PubMed Web of Science ®Google Scholar
• Haertzen C. A., Kocher T. R., Miyasato K. Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend. 1983; 11(2)147–165
   PubMed Web of Science ®Google Scholar
• Fergusson D. M., Horwood L. J., Lynskey M. T., Madden P. A. Early reactions to cannabis predict later dependence. Arch Gen Psychiatry. 2003; 60(10)1033–1039
   PubMed Web of Science ®Google Scholar
• Gulley J. M., Everett C. V., Zahniser N. R. Inbred Lewis and Fischer 344 rat strains differ not only in novelty- and amphetamine-induced behaviors, but also in dopamine transporter activity in vivo. Brain Res. 2007; 1151(2)32–45
   PubMed Web of Science ®Google Scholar
• Haile C. N., Zhang X. Y., Carroll F. I., Kosten T. A. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res. 2005; 1055(1–2)186–95
   PubMed Web of Science ®Google Scholar
• Lake C. R., Quirk R. S. CNS stimulants and the look-alike drugs. Psychiatr Clin North Am 1984; 7: 689–701
   PubMed Web of Science ®Google Scholar
• Cook C. E., Jeffcoat A. R., Hill J. M., Pugh D. E., Patetta P. K., Sadler B. M., White W. R., Perez-Reyes M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos. 1993; 21: 717–723
   PubMed Web of Science ®Google Scholar
• Fischman M. W., Schuster C. R. Tolerance development to chronic methampetamine intoxication in the rhesus monkey. Pharmacol Biochem Behav. 1974; 2: 503–508
   PubMed Web of Science ®Google Scholar
• Perez-Reyes M., White W. R., McDonald S. A., Hicks R. E., Jeffcoat A. R., Hill J. M., Cook C. E. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol. 1991; 14: 352–358
   PubMed Web of Science ®Google Scholar
• Martin W. R., Sloan J. W., Sapira J. D., Jasinski D. R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971; 12: 245–248
   PubMed Web of Science ®Google Scholar
• Gawin F. H., Ellinwood E. H. J. Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med. 1988; 318: 1173–1182
   PubMed Web of Science ®Google Scholar
• Cretzmeyer M., Sarrazin M. V., Huber D. L., Block R. I., Hall J. A. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat. 2003; 24: 267–277
   PubMed Web of Science ®Google Scholar
• Newton T. F., Kalechstein A. D., Duran S., Vansluis N., Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004; 13: 248–255
   PubMed Web of Science ®Google Scholar
• Srisurapanont M., Ali R., Marsden J., Sunga A., Wada K., Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003; 6: 347–352
   PubMed Web of Science ®Google Scholar
• Yui K., Ikemoto S., Ishiguro T., Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 2000; 914: 1–12
   PubMed Web of Science ®Google Scholar
• Akiyama K., Kanzaki A., Tsuchida K., Ujike H. Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophrenia Res. 1994; 12: 251–257
   PubMed Web of Science ®Google Scholar
• Rose M. E., Grant J. E. Pharmacotherapy for methamaphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 2008; 20(3)145–155
   PubMed Web of Science ®Google Scholar
• Zetterstrom T., Sharp T., Collin A. K., Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 1988; 148: 327–334
   PubMed Web of Science ®Google Scholar
• Fischer J., Cho A. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979; 208: 203–209
   PubMed Web of Science ®Google Scholar
• Cubells J. F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994; 14(4)2260–71
   PubMed Web of Science ®Google Scholar
• Liu Y., Edwards R. H. The role of vesicular transport porteins in synaptic transmission and neural degeneration. Annu Rev Neurosci. 1997; 20: 125–156
   PubMed Web of Science ®Google Scholar
• Berman S. B., Zigmond M. J., Hastings T. G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem. 1996; 67: 593–600
   PubMed Web of Science ®Google Scholar
• Fleckenstein A. E., Metzger R. R., Beyeler M. L., Gibb J. W., Hanson G. R. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol. 1997; 334: 111–114
   PubMed Web of Science ®Google Scholar
• Kokoshka J. M., Vaughan R. A., Hanson G. R., Fleckenstein A. E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol. 1998; 361: 269–275
   PubMed Web of Science ®Google Scholar
• Davidson C., Gow A. J., Lee T. H., Ellinwood E. H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 2001; 36: 1–22
   PubMed Web of Science ®Google Scholar
• Cho A. K., Melega W. P. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002; 21: 21–34
   PubMed Web of Science ®Google Scholar
• Kita T., Wagner G. C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci. 2003; 92: 178–195
   PubMed Web of Science ®Google Scholar
• Metzger R. R., Haughey H. M., Wilkins D. G., Gibb J. W., Hanson G. R., Fleckenstein A. E. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther. 2000; 295: 1077–1085
   PubMed Web of Science ®Google Scholar
• Ujike H., Onoue T., Akiyama K., Hamamura T., Otsuki S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 1989; 98: 89–92
   PubMed Web of Science ®Google Scholar
• Witkin J. M., Savtchenko N., Mashkovsky M., Beekman M., Munzar P., Gasior M., Goldberg S. R., Ungard J. T., Kim J., Shippenberg T., Chefer V. Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. J Pharmacol Exp Ther. 1999; 288: 1298–1310
   PubMed Web of Science ®Google Scholar
• Wong A. H. C., VanTol H. H. M. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1091–1099
   PubMed Web of Science ®Google Scholar
• Okuyama S., Kawashima N., Chaki S., Yoshikawa R., Funakoshi T., Ogawa S. I., Suzuki Y., Ideda Y., Kumagai T., Nakazato A., Nagamine M., Tomisawa K. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile. Life Sci. 1999; 65: 2109–2125
   PubMed Web of Science ®Google Scholar
• Kamei H., Nagai T., Nakano H., Togan Y., Takayanagi M., Takahashi K., Kobayashi K., Yoshida S., Maeda K., Takuma K., Nabeshima T., Yamada K. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 2006; 59(1)75–84
   PubMed Web of Science ®Google Scholar
• Wachtel S. R., Ortengren A., de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002; 68(1)23–33
   PubMed Web of Science ®Google Scholar
• McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F., Ricaurte G. A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998; 18: 8417–8422
   PubMed Web of Science ®Google Scholar
• Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001; 58: 1206–1214
   Web of Science ®Google Scholar
• Iyo M., Sekine Y., Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci. 2004; 1025: 288–295
   PubMed Web of Science ®Google Scholar
• Chen C. K., Hu X., Lin S. K., Sham P. C.el-W, L., Li T., Murray R. M., Ball D. M. Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psychiatr Genet. 2004; 14(4)223–6
   PubMed Web of Science ®Google Scholar
• Liu H. C., Lin S. K., Liu S. K., Chen S. L., Hu C. J., Chang J. G., Leu S. J. DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. Psychiatr Genet. 2004; 14(1)33–7
   PubMed Web of Science ®Google Scholar
• Vandenbergh D. J., Rodriguez L. A., Hivert E., Schiller J. H., Villareal G., Pugh E. W., Lachman H., Uhl G. R. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. Am J Med Genet. 2000; 96(5)678–83
   PubMed Web of Science ®Google Scholar
• Hosák L., Libiger J., Cizek J., Beránek M., Cermáková E. The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: preliminary results. Neuro Endocrinol Lett. 2006; 27(6)799–802
   PubMed Web of Science ®Google Scholar
• Suzuki A., Nakamura K., Sekine Y., Minabe Y., Takei N., Suzuki K., Iwata Y., Kawai M., Takebayashi K., Matsuzaki H., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Mori N. An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet. 2006; 16(4)133–8
   PubMed Web of Science ®Google Scholar
• Ujike H., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Sora I., Iyo M., Katsu T., Nomura A., Nakata K., Ozaki N. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenetics J. 2003; 3(4)242–247
   PubMed Web of Science ®Google Scholar
• Matsuzawa D., Hashimoto K., Miyatake R., Shirayama Y., Shimizu E., Maeda K., Suzuki Y., Mashimo Y., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Hata A., Sawa A., Iyo M. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007; 164(7)1105–14
   PubMed Web of Science ®Google Scholar
• Zimniak P., Nanduri B., Pikua S., Bandorowicz-Pikua J., Singhal S. S., Srivastava S. K., Awasthi S., Awasthi Y. C. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994; 224(3)893–9
   PubMedGoogle Scholar
• Hashimoto T., Hashimoto K., Matsuzawa D., Shimizu E., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2005; 135(1)5–9
   Web of Science ®Google Scholar
• Aoyama N., Takahashi N., Kitaichi K., Ishihara R., Saito S., Maeno N., Ji X., Takagi K., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iwata N., Inada T., Ozaki N. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res. 2006; 30(10)1644–9
   PubMed Web of Science ®Google Scholar
• Ikeda M., Ozaki N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Kishi T., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Iwata N. Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav. 2007; 6(1)107–12
   PubMed Web of Science ®Google Scholar
• Ide S., Kobayashi H., Tanaka K., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Ikeda K., Sora I. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci. 2004; 1025: 316–24, (Oct)
   PubMed Web of Science ®Google Scholar
• Ide S., Kobayashi H., Ujike H., Ozaki N., Sekine Y., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Iwata N., Tanaka K., Shen H., Iwahashi K., Itokawa M., Minami M., Satoh M., Ikeda K., Sora I. Linkage disequilibrium and association with methamphetamine dependence/psychosis of muopioid receptor gene polymorphisms. Pharmacogenomics J. 2006; 6(3)179–88
   PubMed Web of Science ®Google Scholar
• Kobayashi H., Hata H., Ujike H., Harano M., Inada T., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Ozaki N., Itokawa M., Naka M., Ide S., Ikeda K., Numachi Y., Sora I. Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis. Am J Med Genet B Neuropsychiatr Genet. 2006; 141(5)482–6
   Web of Science ®Google Scholar
• Poo M. M. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001; 2(1)24–32
   PubMed Web of Science ®Google Scholar
• Tyler W. J., Alonso M., Bramham C. R., Pozzo-Miller L. D. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem. 2002; 9(5)224–37
   PubMed Web of Science ®Google Scholar
• Horger B. A., Iyasere C. A., Berhow M. T., Messer C. J., Nestler E. J., Taylor J. R. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci. 1999; 19(10)4110–22
   PubMed Web of Science ®Google Scholar
• Bolaños C. A., Nestler E. J. Neurotrophic mechanisms in drug addiction. Neuromolecular Med. 2004; 5(1)69–83
   PubMed Web of Science ®Google Scholar
• Jockers-Scherübl M. C., Danker-Hopfe H., Mahlberg R., Selig F., Rentzsch J., Schürer F., Lang U. E., Hellweg R. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett. 2004; 371(1)79–83
   PubMed Web of Science ®Google Scholar
• Egan M. F., Kojima M., Callicott J. H., Goldberg T. E., Kolachana B. S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D. R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003; 112(2)257–69
   PubMed Web of Science ®Google Scholar
• Cheng C. Y., Hong C. J., Yu Y. W., Chen T. J., Wu H. C., Tsai S. J. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res. 2005; 140(1–2)86–90
   PubMedGoogle Scholar
• Hariri A. R., Goldberg T. E., Mattay V. S., Kolachana B. S., Callicott J. H., Egan M. F., Weinberger D. R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003; 23(17)6690–4
   PubMed Web of Science ®Google Scholar
• Liu Q. R., Walther D., Drgon T., Polesskaya O., Lesnick T. G., Strain K. J., de Andrade M., Bower J. H., Maraganore D. M., Uhl G. R. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet. 2005; 134(1)93–103
   Web of Science ®Google Scholar